Innovators in Cancer Immunology: Lung Cancer

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics^™ Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Research and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. David Rimm, a pioneer of quantitative immunohistochemistry and inventor of AQUA^® technology, focuses on predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer. Dr. Rimm is working closely with PerkinElmer to bring rigor to the development of Phenoptics to make it a truly quantitative approach by helping to establish consistent Opal^™ staining methods and expression measurement controls. He is particularly interested in exploring the per-cell and spatial parameters enabled by Phenoptics. Dr. Rimm’s first project evaluated Tumor Infiltrating Lymphocyte (TIL) status in a lung cancer Thrombotic Microangiopathy (TMA).